Nisha Joseph, MD

Panelists discuss the data surrounding the use of CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM), including findings from the cilta-cel (Popat R, et al. ASH 2024 No. 1032; Mateos MV, et al. IMS 2024 No. OA-65), and Idel-cel (Ailawadhi S, et al. Blood 2024) studies, and share their thoughts on the implications of these results.

Final remarks and presentation of awards.

Experts discuss the Phase 2 D-ALBA trial results examining combination of dasatinib plus blinatumomab as frontline therapy for adults with Philadelphia chromosome-positive B cell acute lymphoblastic leukemia.

Experts provide extended follow-up on efficacy and safety outcomes with initial therapy combining ponatinib and hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Experts present findings on blinatumomab consolidation therapy from the Phase 3 ECOG-ACRIN E1910 trial in adult patients with newly diagnosed B-lineage acute lymphoblastic leukemia who achieved measurable residual disease-negative remission.

Experts provide the first report of results from the Phase 3 PhALLCON trial comparing initial therapy with ponatinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Examine the efficacy and safety of the BCMA-targeting bispecific antibody elranatamab as monotherapy and in combinations from the Phase 2 MagnetisMM-3 trial in patients with relapsed or refractory multiple myeloma.

Present initial results from the Phase 1 RedirecTT-1 trial exploring the combination of teclistamab and talquetamab in relapsed/refractory multiple myeloma.

Compare outcomes between ide-cel chimeric antigen receptor T-cell (CAR-T) therapy and standard treatment regimens such as pomalidomide and daratumumab combinations in patients with heavily pretreated relapsed and refractory multiple myeloma.

Present real-world data on the efficacy and safety of the ixazomib-lenalidomide-dexamethasone combination in patients with relapsed/refractory multiple myeloma outside of clinical trials.

Examine outcomes such as overall survival, progression-free survival, and response rates in multiple myeloma patients who have experienced biochemical or clinical progression after prior lines of therapy.

A summary of key discussion points and an overview of the evidence presented to inform the dialogue.

Subject matter experts share strategies for determining treatment selection and duration for patients with transplant-ineligible NDMM.

Subject matter experts share strategies for determining treatment selection and duration for patients with transplant-ineligible NDMM.

Ajay Nooka, MD, MPH, FACP leads a survey of the MAIA study, including a sub-group analysis of the MAIA study in frail patients, as well as findings from the MagnetisMM-6 study.

Jonathan Kaufman, MD describes a second patient case featuring a 76-year-old female diagnosed with transplant-ineligible NDMM.

Defining transplant eligibility, explaining the role of transplant in NDMM, and differentiating between high- and low-risk MM.

Thoughtful discussion centered around recently presented updates to the GRIFFIN, MASTER, and GMMG-CONCEPT studies in NDMM patients.

Nisha Joseph, MD leads an introduction to induction regimen options for patients with transplant-eligible NDMM.

Moderator Sagar Lonial, MD, FACP, and colleagues engage with the first patient case: a 65-year-old female diagnosed with transplant-eligible NDMM.

Experts muse on the unmet needs of multiple myeloma, and exciting investigational therapies on the horizon.

A look at the role of bispecifics and CAR T-cell therapies in the multiple myeloma treatment landscape.

Experts discuss the case of a woman with relapsed/refractory multiple myeloma and the available treatment options, including novel BCMA-targeted agents.

Key opinion leaders describe the role of blood-based MRD testing in the transplant-ineligible multiple myeloma treatment landscape.

Nisha Joseph, MD, presents the case of a 78-year-old man with transplant-ineligible multiple myeloma and discusses treatment strategy.

Experts discuss how they define frail and high-risk patients with multiple myeloma and their treatment approaches for these patient populations.

An overview of the study design, efficacy, and safety findings of the MAIA trial.

Dr Nisha Joseph presents the case of a woman with transplant-ineligible multiple myeloma and discusses considerations when choosing frontline treatment regimens.

Drs Ajay Nooka and Jonathan Kaufman discuss maintenance and consolidation treatment strategies for transplant eligible multiple myeloma.

Experts discuss how they select a treatment regimen for a newly diagnosed multiple myeloma patient, and how they measure a successful treatment response.